Skip Nav Destination
Issues
1 October 2021
-
Cover Image
Cover Image
The cover shows a section of a breast biopsy from a patient with triple-negative breast cancer. Multiplex immunofluorescence shows high CD3+ T-cell infiltration (red) and low CD68+ immune cell infiltration (yellow) in the tumor-immune microenvironment. For details, see the article by Yam and colleagues on page 5365 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Regulatory Science and Policy
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
Julie A. Schneider; Yutao Gong; Kirsten B. Goldberg; Paul G. Kluetz; Marc R. Theoret; Laleh Amiri-Kordestani; Julia A. Beaver; Lola Fashoyin-Aje; Nicole J. Gormley; Adnan A. Jaigirdar; Steven J. Lemery; Pallavi S. Mishra-Kalyani; Gregory H. Reaman; Donna R. Rivera; Wendy S. Rubinstein; Harpreet Singh; Rajeshwari Sridhara; Richard Pazdur
Reviews
Perspectives
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Kenneth C. Anderson; Daniel Auclair; Stacey J. Adam; Amit Agarwal; Melissa Anderson; Hervé Avet-Loiseau; Mark Bustoros; Jessica Chapman; Dana E. Connors; Ajeeta Dash; Alessandra Di Bacco; Ling Du; Thierry Facon; Juan Flores-Montero; Francesca Gay; Irene M. Ghobrial; Nicole J. Gormley; Ira Gupta; Howard Higley; Jens Hillengass; Bindu Kanapuru; Dickran Kazandjian; Gary J. Kelloff; Ilan R. Kirsch; Brandon Kremer; Ola Landgren; Elizabeth Lightbody; Oliver C. Lomas; Sagar Lonial; María-Victoria Mateos; Rocio Montes de Oca; Lata Mukundan; Nikhil C. Munshi; Elizabeth K. O'Donnell; Alberto Orfao; Bruno Paiva; Reshma Patel; Trevor J. Pugh; Karthik Ramasamy; Jill Ray; Mikhail Roshal; Jeremy A. Ross; Caroline C. Sigman; Katie L. Thoren; Suzanne Trudel; Gary Ulaner; Nancy Valente; Brendan M. Weiss; Elena Zamagni; Shaji K. Kumar
Clinical Trials: Targeted Therapy
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A. Yap; Matthew G. Krebs; Sophie Postel-Vinay; Anthony El-Khouiery; Jean-Charles Soria; Juanita Lopez; Alienor Berges; S.Y. Amy Cheung; Itziar Irurzun-Arana; Andrew Goldwin; Brunella Felicetti; Gemma N. Jones; Alan Lau; Paul Frewer; Andrew J. Pierce; Glen Clack; Christine Stephens; Simon A. Smith; Emma Dean; Simon J. Hollingsworth
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A. Ascierto; Brigitte Dréno; James Larkin; Antoni Ribas; Gabriella Liszkay; Michele Maio; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Victoria Atkinson; Caroline Dutriaux; Claus Garbe; Jessie Hsu; Surai Jones; Haocheng Li; Edward McKenna; Athina Voulgari; Grant A. McArthur
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N. Saleh; Manish R. Patel; Todd M. Bauer; Sanjay Goel; Gerald S. Falchook; Geoffrey I. Shapiro; Ki Y. Chung; Jeffrey R. Infante; Robert M. Conry; Guilherme Rabinowits; David S. Hong; Judy S. Wang; Ulrich Steidl; Gurudatta Naik; Vincent Guerlavais; Vojislav Vukovic; D. Allen Annis; Manuel Aivado; Funda Meric-Bernstam
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Debashis Sarker; Nancy A. Dawson; Ana M. Aparicio; Tanya B. Dorff; Allan J. Pantuck; Ulka N. Vaishampayan; Lynn Henson; Lakshmi Vasist; Sumita Roy-Ghanta; Michele Gorczyca; Whitney York; Gopinath Ganji; Jerry Tolson; Johann S. de Bono
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
Kazuhiko Nakagawa; Ernest Nadal; Edward B. Garon; Makoto Nishio; Takashi Seto; Nobuyuki Yamamoto; Keunchil Park; Jin-Yuan Shih; Luis Paz-Ares; Bente Frimodt-Moller; Annamaria H. Zimmermann; Sameera Wijayawardana; Carla Visseren-Grul; Martin Reck; for the RELAY study investigators
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma
Eun Joo Kang; Myung-Ju Ahn; Chan-Young Ock; Keun-Wook Lee; Jung Hye Kwon; Yaewon Yang; Yoon Hee Choi; Min Kyoung Kim; Jun Ho Ji; Tak Yun; Byung-Ho Nam; Sung-Bae Kim; Bhumsuk Keam
Clinical Trials: Immunotherapy
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V. Long; Caroline Robert; Marcus O. Butler; Felix Couture; Matteo S. Carlino; Steven O'Day; Victoria Atkinson; Jonathan S. Cebon; Michael P. Brown; Stéphane Dalle; Andrew G. Hill; Geoffrey T. Gibney; Steven McCune; Alexander M. Menzies; Cuizhen Niu; Nageatte Ibrahim; Blanca Homet Moreno; Adi Diab
Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
Samantha J. Seitter; Richard M. Sherry; James C. Yang; Paul F. Robbins; Mackenzie L. Shindorf; Amy R. Copeland; Christine T. McGowan; Monica Epstein; Thomas E. Shelton; Michelle M. Langhan; Zulmarie Franco; David N. Danforth; Donald E. White; Steven A. Rosenberg; Stephanie L. Goff
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
Paula I. Gonzalez-Ericsson; Julia D. Wulfkhule; Rosa I. Gallagher; Xiaopeng Sun; Margaret L. Axelrod; Quanhu Sheng; Na Luo; Henry Gomez; Violeta Sanchez; Melinda Sanders; Lajos Pusztai; Emanuel Petricoin; Kim R.M. Blenman; Justin M. Balko; I-SPY2 Trial Team
Precision Medicine and Imaging
A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization
Xavier Sastre-Garau; Mamadou Diop; Fernando Martin; Gilles Dolivet; Frédéric Marchal; Claire Charra-Brunaud; Didier Peiffert; Léa Leufflen; Birama Dembélé; Jessica Demange; Priscillia Tosti; Jacques Thomas; Agnès Leroux; Jean-Louis Merlin; Halimatou Diop-Ndiaye; Jean-Marc Costa; Julia Salleron; Alexandre Harlé
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Laura Kist de Ruijter; Jahlisa S. Hooiveld-Noeken; Danique Giesen; Marjolijn N. Lub-de Hooge; Iris C. Kok; Adrienne H. Brouwers; Sjoerd G. Elias; Margaret T.L. Nguyen; Hong Lu; Jourik A. Gietema; Mathilde Jalving; Derk J.A. de Groot; Olga Vasiljeva; Elisabeth G.E. de Vries
Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity
Ashwyn K. Sharma; Jorge de la Torre; Nikki S. IJzerman; Thomas L. Sutton; Beiqun Zhao; Tahsin M. Khan; Sudeep Banerjee; Christina Cui; Vi Nguyen; Maha Alkhuziem; Petur Snaebjornsson; Hester van Boven; Annemarie Bruining; Chih-Min Tang; Hyunho Yoon; Alexa De la Fuente; Shumei Kato; Hitendra Patel; Michael C. Heinrich; Christopher L. Corless; Santiago Horgan; Adam M. Burgoyne; Paul Fanta; Jill P. Mesirov; Andrew M. Blakely; Jeremy L. Davis; Skye C. Mayo; Winan J. van Houdt; Neeltje Steeghs; Jason K. Sicklick
Translational Cancer Mechanisms and Therapy
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Clinton Yam; Er-Yen Yen; Jeffrey T. Chang; Roland L. Bassett, Jr; Gheath Alatrash; Haven Garber; Lei Huo; Fei Yang; Anne V. Philips; Qing-Qing Ding; Bora Lim; Naoto T. Ueno; Kasthuri Kannan; Xiangjie Sun; Baohua Sun; Edwin Roger Parra Cuentas; William Fraser Symmans; Jason B. White; Elizabeth Ravenberg; Sahil Seth; Jennifer L. Guerriero; Gaiane M. Rauch; Senthil Damodaran; Jennifer K. Litton; Jennifer A. Wargo; Gabriel N. Hortobagyi; Andrew Futreal; Ignacio I. Wistuba; Ryan Sun; Stacy L. Moulder; Elizabeth A. Mittendorf
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Lijie Xing; Su Wang; Jiye Liu; Tengteng Yu; Hailin Chen; Kenneth Wen; Yuyin Li; Liang Lin; Phillip A. Hsieh; Shih-Feng Cho; Gang An; Lugui Qiu; Krista Kinneer; Nikhil Munshi; Kenneth C. Anderson; Yu-Tzu Tai
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
Oscar Krijgsman; Kristel Kemper; Julia Boshuizen; David W. Vredevoogd; Elisa A. Rozeman; Sofia Ibanez Molero; Beaunelle de Bruijn; Paulien Cornelissen-Steijger; Aida Shahrabi; Martin Del Castillo Velasco-Herrera; Ji-Ying Song; Maarten A. Ligtenberg; Roelof J.C. Kluin; Thomas Kuilman; Petra Ross-Macdonald; John B.A.G. Haanen; David J. Adams; Christian U. Blank; Daniel S. Peeper
Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
Kit I. Tong; Sharon Yoon; Keren Isaev; Mehran Bakhtiari; Tracy Lackraj; Michael Y. He; Jesse Joynt; Anjali Silva; Maria C. Xu; Gilbert G. Privé; Housheng Hansen He; Rodger E. Tiedemann; Elizabeth A. Chavez; Lauren C. Chong; Merrill Boyle; David W. Scott; Christian Steidl; Robert Kridel
PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Rama Krishna Nimmakayala; Sanchita Rauth; Ramakanth Chirravuri Venkata; Saravanakumar Marimuthu; Palanisamy Nallasamy; Raghupathy Vengoji; Subodh M. Lele; Satyanarayana Rachagani; Kavita Mallya; Mokenge P. Malafa; Moorthy P. Ponnusamy; Surinder K. Batra
The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
Neeraj Sharma; James B. Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E. Pearce; Yan W. Asmann; Jess F. Peterson; Rhett P. Ketterling; Patricia T. Greipp; P. Leif Bergsagel; S. Vincent Rajkumar; Shaji K. Kumar; Linda B. Baughn
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds